In a recent revelation, a hidden agreement has come to light, impacting the healthcare landscape in Australia. This obscure deal, made just before the 2022 federal election, has locked millions of privately insured Australians into paying exorbitant prices for medical devices. The agreement, which went against the advice of federal bureaucrats, has created a system where patients are paying some of the highest prices globally for surgical hardware.
What makes this particularly fascinating is the intricate web of interests involved. The deal, endorsed by both the previous and current health ministers, has resulted in a price-setting schedule known as the Prescribed List. This list dictates the prices private health funds must pay for over 10,000 medical items, often at rates significantly higher than those in public hospitals. Privately insured Australians are paying up to three times more, and critics argue that these prices contribute to rising insurance premiums.
The Impact on Patients and Profits
One thing that immediately stands out is the isolation of medical device manufacturers from normal commercial competition. This system forces policyholders to subsidize corporate profits, creating a legalized wealth transfer. Health economist Stephen Duckett describes it as a situation where private patients are paying a price floor that is far higher than what public hospitals pay for the same products. This raises a deeper question about the fairness and accessibility of healthcare for privately insured individuals.
A System of Disparity
The current system has created severe price gaps between Australia and other health systems, such as those in New Zealand, Britain, and France. Official data reveals these disparities across various medical devices, including defibrillators, artificial joints, and pacemakers. For instance, the private Prescribed List benefit for an implanted cardiac defibrillator was $36,500 in 2023, while public hospitals paid $14,500 for the same device. This disparity is a cause for concern, as it highlights the potential for profit-driven decisions to impact patient care.
The Role of Negotiation
In contrast to the Pharmaceutical Benefits Scheme, where bureaucrats negotiate directly with pharmaceutical firms, the Prescribed List sets prices through an advisory committee. This committee reviews prices three times a year, but the inclusion of a mandatory price floor for devices, at 7% above public hospital rates, has drawn criticism. Internal documents show that public servants refused to endorse this agreement, citing financial risks and uncosted concessions. Despite these warnings, the deal was pushed through, leaving a lasting impact on the medical devices market.
The Financial Implications
The latest figures show that private health funds paid $2.52 billion for medical devices in the year to March 2026, a 3.2% increase from the previous year. This increase in spending is significant, especially when compared to the 1.8% growth in private hospital admissions over the same period. Private Healthcare Australia CEO Dr. Rachel David highlights that the Prescribed List agreement has transferred hundreds of millions of dollars from health insurance policyholders to private hospitals and device manufacturers. This transfer of wealth is a concerning trend, as it suggests that patients are bearing the brunt of these inflated prices.
A Complex Web of Interests
The medical devices industry argues that the issue lies with private health insurers, claiming that they pocket the savings rather than reducing insurance premiums. Ian Burgess, CEO of the Medical Technology Association of Australia, rejects direct price comparisons with overseas markets, citing differences in funding models. However, the Nous Group's review of the Prescribed List reforms acknowledged that Australian device prices are artificially high compared to overseas markets. This review recommended an urgent review of international benchmarking in benefit setting.
Conclusion
This obscure agreement has created a complex web of interests, impacting patients, manufacturers, and insurers. The system has resulted in significantly higher prices for privately insured Australians, raising questions about the accessibility and fairness of healthcare. As we delve deeper into this issue, it becomes clear that a comprehensive review and potential reform of the Prescribed List is necessary to ensure a more equitable healthcare system for all Australians.
